99790-15-5

Upstream product

• 1142-20-7 N-Cbz-Ala 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 114744-83-1 (S)-benzyl (1-(N,O-dimethylhydroxylamine)-1-oxopropan-2-yl)carbamate 
• 866555-33-1 (2S,3S)-2-{[(S)-2-Azido-3-((S)-2-benzyloxycarbonylamino-propionyloxy)-2-methyl-propionyl]-methyl-amino}-3-methyl-pentanoic acid methyl ester 
• 866555-16-0 (2S,3S)-2-{[(S)-2-Azido-3-((S)-2-benzyloxycarbonylamino-propionyloxy)-2-methyl-propionyl]-methyl-amino}-5-(tert-butyl-diphenyl-silanyloxy)-3-methyl-pentanoic acid methyl ester 
• 6429-44-3 (S)-(-)-N-(benzyloxycarbonyl)alaninol 
• 198955-60-1 (2S)-2-(benzyloxycarbonylamino)-1-(oxazolo[4,5,b]pyridin-2-yl)-1-propanol 
• 198955-61-2 (2S)-2-(benzyloxycarbonylamino)-1-(4-methylbenzo[d][1,3]oxazol-2-yl)-1-propanol 
• 198955-64-5 (2S)-2-(benzyloxycarbonylamino)-1-(7-methylbenzo[d][1,3]oxazol-2-yl)-1-propanol 
• 198955-59-8 (2S)-2-(benzyloxycarbonylamino)-1-benzo[d][1,3]oxazol-2-yl-1-propanol 
• 198955-62-3 (2S)-2-(benzyloxycarbonylamino)-1-(5-methylbenzo[d][1,3]oxazol-2-yl)-1-propanol 
• 198955-63-4 (2S)-2-(benzyloxycarbonylamino)-1-(6-methylbenzo[d][1,3]oxazol-2-yl)-1-propanol 
• 198956-41-1 ((2S)-1-cyano-1-hydroxypropan-2-yl)carbamic acid benzyl ester 
• 82353-55-7 benzyl (S)-1-oxopropan-2-ylcarbamate 
• 866555-17-1 (2S,3S)-2-{[(S)-2-((S)-1-Benzyloxycarbonylamino-ethyl)-4-methyl-4,5-dihydro-oxazole-4-carbonyl]-methyl-amino}-5-(tert-butyl-diphenyl-silanyloxy)-3-methyl-pentanoic acid methyl ester 
• 866555-34-2 (2S,3S)-2-{[(S)-2-((S)-1-Benzyloxycarbonylamino-ethyl)-4-methyl-4,5-dihydro-oxazole-4-carbonyl]-methyl-amino}-3-methyl-pentanoic acid methyl ester 

Relevant academic research and scientific papers

N-carbamate protected amino acid derived guanidine organocatalysts

We report the preparation of a range of N-protected amino acid derived guanidine organocatalysts and their application to the Michael addition of 2-hydroxy-1,4-napthoquinone to β-nitrostyrene, achieving a maximum ee of 26%. Whilst these catalysts gave poo

Synthesis and preliminary biological evaluations of (+)-isocampholenic acid-derived amides

The synthesis of two novel (+)-isocampholenic acid-derived amines has been realized starting from commercially available (1S)-(+)-10-camphorsulfonic acid. The novel amines as well as (+)-isocampholenic acid have been used as building blocks in the constru

A rapid and efficient one-pot method for the reduction of N-protected α-amino acids to chiral α-amino aldehydes using CDI/DIBAL-H

N-Protected amino acids can be easily converted into chiral α-amino aldehydes in a one-pot reaction by activation with CDI followed by reduction with DIBAL-H. This method delivers Boc-, Cbz- and Fmoc-protected amino aldehydes from proteinogenic amino acids in very good isolated yields and complete stereointegrity.

INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS

Disclosed is a method of making a 1-alkylindazole comprising reacting a 1-acylindazole with a first reducing agent, and contacting the resulting mixture with an acid anhydride or acyl halide, and with pyridine or a 4-dialkylaminopyridine or a combination

Total synthesis of halipeptins A and D and analogues

(Chemical Equation Presented) Deceptive rings: Halipeptins A (1 a) and D (1 b) and analogues thereof were synthesized from fragments 2 and 3 a, b, respectively. Key steps included peptide-bond formation, DAST-induced thiazoline construction, and macrolact

Peptidomimetic inhibitors of the human cytomegalovirus protease

The development of peptidomimetic inhibitors of the human cytomegalovirus (HCMV) protease showing sub-micromolar potency in an enzymatic assay is described. Selective substitution of the amino acid residues of these inhibitors led to the identification of tripeptide inhibitors showing improvements in inhibitor potency of 27-fold relative to inhibitor 39 based upon the natural tetrapeptide sequence. Small side chains at P1 were well tolerated by this enzyme, a fact consistent with previous observations. The S2 binding pocket of HCMV protease was very permissive, tolerating lipophilic and basic residues. The substitutions tried at P3 indicated that a small increase in inhibitor potency could be realized by the substitution of a tert-leucine residue for valine. Substitutions of the N- terminal capping group did not significantly affect inhibitor potency. Pentafluoroethyl ketones, α,α-difluoro-β-keto amides, phosphonates and α- keto amides were all effective substitutions for the activated carbonyl component and gave inhibitors which were selective for HCMV protease. A slight increase in potency was observed by lengthening the P1' residue of the α-keto amide series of inhibitors. This position also tolerated a variety of groups making this a potential site for future modifications which could modulate the physicochemical properties of these molecules.

Synthesis and antitumor activity of novel dolastatin 10 analogs

Dolastatin 10 (1) is a potent antineoplastic pentapeptide. Novel dolastatin 10 analogs each modified at one of the constituent amino acid derivatives, were synthesized and their antitumor activity was evaluated against P388 leukemia in mice. The structural requirements for antitumor activity are discussed. Some of the analogs, 31c, 35c, 38b, and 50c showed excellent activity in vivo. Highly active 50c, which lacks the thiazole group of 1, was selected for further development as an antitumor agent.